Neogen Earnings Call: Food Safety Strength Amid Strain

Neogen ((NEOG)) has held its Q3 earnings call. Read on for the main highlights of the call.

Neogen’s latest earnings call painted a cautious but constructive picture, with management balancing improving execution in Food Safety, stronger margins, and positive free cash flow against persistent headwinds in Animal Safety, logistics and foreign exchange. Leadership stressed that a multi-year transformation, portfolio pruning, and debt reduction should unlock value, but near-term volatility will likely cap upside.

Stable Top Line With Minimal Core Growth

Neogen reported third-quarter revenue of $211.2 million, with core revenue essentially flat at plus 0.1% year over year, underscoring resilience in a mixed macro and end-market backdrop. While hardly a growth story this quarter, management framed the stable top line as a base from which to drive margin expansion and strategic repositioning.

Food Safety Segment Drives Growth

Food Safety remained the growth engine, generating $156.7 million in revenue and 4% core growth as customers continued to prioritize reliable testing solutions. Indicator testing led the way with 11% growth, and pathogen test kits also performed well, reinforcing Neogen’s positioning as a critical supplier amid rising regulatory and recall scrutiny.

Margins Tick Higher as Profitability Improves

Adjusted EBITDA reached $48.2 million, translating to a 22.8% margin and a sequential expansion of about 110 basis points that signals early benefits from cost actions and mix. Adjusted gross margin came in at 51.7% and reported gross margin at 46.9%, which would have been essentially flat versus last year when stripping out one-time transition costs.

Free Cash Flow Positive and Portfolio Pruning

Free cash flow for the quarter was $11.1 million and is positive year to date, giving the company more flexibility to fund its transformation while managing leverage. Neogen also announced the sale of its genomics business for $160 million, with roughly $140 million of net proceeds earmarked to reduce debt and help drive net debt to adjusted EBITDA below three times by 2026.

Petrifilm Manufacturing Transition on Track

The company reported steady progress on its Petrifilm manufacturing transition, with full validation completed on all production equipment and SKU-specific validations underway. Bringing production fully in house is expected to lift contribution margins on incremental Petrifilm revenue while enabling custom SKUs and faster prototyping once a dedicated research-scale line is funded.

Cost Discipline Supports Operating Leverage

Adjusted operating expenses declined about 9% sequentially from the second quarter, reflecting tighter cost control and restructuring efforts across the organization. Management signaled continued scrutiny on operating expenses, with spending to be prioritized toward value-creating transformation projects rather than broad-based expansion.

Transformation Plan Targets Commercial, Innovation and Efficiency

Neogen outlined a three-pronged transformation program centered on sharpening commercial execution, accelerating high-impact innovation, and boosting operational efficiency. This includes new global commercial leadership, a shift toward solutions-based selling, expanded Petrifilm offerings, as well as improved planning, greater supplier control, and data- and AI-enabled supply chain management.

Regulatory and Recall Trends Support Long-Term Demand

Industry recall activity increased roughly 15% from 2024 to 2025, and the Food and Drug Administration’s recalled volume more than doubled, underscoring rising food-safety risks and enforcement. Management argued that these structural trends support durable demand for robust testing and monitoring solutions, playing directly to Neogen’s core strengths despite short-term noise.

Animal Safety Hit by Supplier Disruptions

Animal Safety was a clear weak spot, posting revenue of $54.5 million and a core decline of 8.7% as multiple third-party supplier issues constrained product availability. Documentation gaps, raw material shortages, site transitions, and tariff-driven shifts combined to disrupt supply, and while fixes are underway, the recovery path remains uneven.

Sample Collection Margins Turn Negative

Within Animal Safety, sample collection products suffered a negative gross margin this quarter, driven by elevated scrap tied to a quality problem at a third-party supplier. The underlying issue has now been addressed and management still expects margins in this category to recover, though progress so far has lagged internal expectations.

Freight and Logistics Costs Erode Profitability

Logistics emerged as another pressure point, with freight and transportation costs rising in the high single-digit to low double-digit percentage range. At current rate levels this represents about $1.5 million in additional cost per quarter, creating a drag on margins that Neogen must offset through price, efficiency, or mix.

FX Shifts from Tailwind to Headwind

After benefiting from currency movements in prior periods, Neogen now expects a stronger U.S. dollar to modestly weigh on reported growth. With around 40% of revenue generated in non-dollar currencies, foreign-exchange volatility will be an ongoing factor for investors to monitor when assessing top-line trends.

Cautious Stance in Near-Term Guidance

Management raised full-year revenue guidance to a range of $857 million to $860 million but kept adjusted EBITDA guidance flat at $175 million, signaling caution around profitability in the near term. The company cited unresolved Animal Safety supply challenges, logistics inflation, and currency headwinds as key reasons to maintain a conservative outlook into the fourth quarter.

Debt Levels and Inventory Still in Focus

Neogen ended the quarter with $800 million in gross debt, about 68% of it fixed rate, and cash of $159.9 million, making deleveraging a priority even as operations stabilize. Inventory levels were flat sequentially, but legacy raw materials and finished goods still pose conversion and write-off risk as the company tightens its planning and inventory management systems.

Some Cost Gains Reflect One-Time Benefits

The sequential drop in operating expenses was flattered by roughly $1 million of nonrecurring credits and other temporary items, suggesting that not all of the improvement will repeat. Management acknowledged these one-time factors and encouraged investors to focus on the underlying trajectory as structural cost actions take hold over the next several quarters.

Guidance Highlights Measured Optimism

Looking ahead, Neogen’s updated targets call for fiscal 2026 revenue of $857 million to $860 million and adjusted EBITDA of $175 million, implying modest growth and continued margin work. Free cash flow is positive and expected to support transformation investments and debt reduction, even as FX, freight, and Animal Safety disruptions keep management’s stance deliberately measured in the short run.

Neogen’s call showed a company in transition, leveraging strength in Food Safety and disciplined cost management to stabilize results while it works through supply, cost, and balance-sheet challenges. Investors will be watching execution on the Petrifilm move in house, the Animal Safety recovery, and the planned deleveraging path to see whether today’s cautious optimism can translate into sustained earnings momentum.